Ribeiro and colleagues review the therapeutic pipeline for psoriatic disease, a prototypic disorder that bridges dermatology, rheumatology, and internal medicine. Despite significant gains with biologics targeting TNF, IL-17, and IL-23, many patients fail to achieve sustained remission, attesting to the disease's heterogeneity. The authors highlight novel agents directed at TYK2 and JAK1, next-generation cytokine inhibitors, and emerging dual biologic or biologic–small molecule combinations.